DISC MEDICINE INC (IRON)
US2546041011 - Common Stock
DISC MEDICINE INC
NASDAQ:IRON (11/4/2024, 8:16:53 PM)
After market: 58.25 0 (0%)58.25
+11.12 (+23.59%)
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS
P: 16176749274
Employees: 78
Website: https://www.discmedicine.com/
IRON News
18 hours ago - ChartmillThese stocks are gapping in today's sessionTraders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
21 hours ago - Disc Medicine IncDisc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval21 hours ago - Disc Medicine IncDisc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated ApprovalAlignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of...
4 days ago - Disc Medicine IncDisc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)4 days ago - Disc Medicine IncDisc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the...
11 days ago - Disc Medicine IncDisc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney WeekIRON Twits
Here you can normally see the latest stock twits on IRON, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
